Atlas Trials

Mobile Devices to Detect Early Pneumonitis in Stage III NSCLC Patients on Durvalumab.

Clinical trial NCT04381494 · TERMINATED

Trial details

NCT number
NCT04381494
Sponsor
AstraZeneca
Status
TERMINATED
Phase
Phase 4
Study type
INTERVENTIONAL
Unresectable Stage III NSCLC
Start date
2020-04-27
Primary completion
2022-01-27
Enrollment
40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.